Gain Therapeutics’ (GANX) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report published on Monday,Benzinga reports. The brokerage currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for Gain Therapeutics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.59) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.56) EPS.

Several other research firms have also recently commented on GANX. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Friday, March 28th. Scotiabank started coverage on Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Gain Therapeutics presently has an average rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Price Performance

Shares of Gain Therapeutics stock opened at $1.81 on Monday. The business has a 50 day simple moving average of $1.93 and a two-hundred day simple moving average of $2.00. Gain Therapeutics has a 12 month low of $0.89 and a 12 month high of $3.19. The stock has a market capitalization of $53.50 million, a P/E ratio of -1.65 and a beta of 0.17. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). As a group, analysts predict that Gain Therapeutics will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GANX. Sprott Inc. purchased a new position in Gain Therapeutics in the fourth quarter worth approximately $30,000. Benedict Financial Advisors Inc. purchased a new position in Gain Therapeutics in the fourth quarter worth approximately $35,000. Bridgeway Capital Management LLC purchased a new position in Gain Therapeutics in the fourth quarter worth approximately $65,000. Kovitz Investment Group Partners LLC purchased a new position in Gain Therapeutics in the first quarter worth approximately $91,000. Finally, Northern Trust Corp grew its position in Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares during the period. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.